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Introduction {#s1}
============

CRC is one of the deadliest diseases worldwide. Caucasian patients with local, regional, or metastatic disease exhibit a 5-year survival rate of 66%, 44%, and 4%, respectively [@pone.0101065-Wingo1]. Disease stage at the time of surgery is well established as the most important prognostic factor in CRC. In the last two decades, median overall survival has increased significantly with the introduction of new cytotoxic agents and biologic therapies. The response to such treatments depends on molecular determinants whose elucidation has been the focus of intense and productive research efforts. We now know, for example, that cancers harboring activating KRAS mutations do not respond to anti-EGFR therapy [@pone.0101065-Newton1]. However, the goal of optimizing treatment protocols based on the unique molecular characteristics of an individual\'s tumor still remains elusive. Development of novel biomarkers that can reliably identify patients at high risk for disease progression and death would be especially useful in determining the clinical circumstances where adjuvant chemotherapy is warranted. Whereas the use of the antimetabolite 5-Fluorouracil (5FU) is standard therapy for patients with stage III CRC, its potential benefits compared to risks in stage II CRC patients is a matter of controversy and debate [@pone.0101065-Cunningham1]. In the absence of a robust clinical predictor of disease outcome, the decision to treat or not to treat stage II patients with 5FU cannot rest on objective and firm criteria. Previously identified predictive biomarkers which had shown great promise in this arena including telomerase, transforming growth factors (TGFα and TGFβ), epidermal growth factors (erbB2 and erbB3) and mucin (MUC1 and MUC2) have disappointed in studies of clinical utility [@pone.0101065-Srivastava1].

The traditional approach to biomarker development relies on single dimensional (microRNA, gene or protein) analysis in an attempt to link a single molecular entity to tumor behavior. This method seems to have reached a zenith that is suboptimal for clinical decision-making. Previous multidimensional approaches have demonstrated that through the combination of biomarkers coming from different dimensions a better knowledge of the biology of CRC can be achieved [@pone.0101065-1], [@pone.0101065-Lee1], [@pone.0101065-Ma1]. In an attempt to provide more personalized options, we developed a novel method that further advances the integration and incorporates multiple molecular entities from all three molecular dimensions (microRNA, genes and protein) simultaneously to generate accurate predictors of outcome in patients with CRC. Our results clearly demonstrate the superiority of this novel, multidimensional approach as compared with the traditional tools of single dimension analysis. We are hopeful that newly discovered multidimensional biomarkers will provide a basis for successful triage and stratification of patients in prospective clinical trials while simultaneously revealing molecular agents and pathways playing prominent sinister roles in CRC disease progression.

Materials and Methods {#s2}
=====================

Gene and micro-RNA expression assessed with nanofluidic technology {#s2a}
------------------------------------------------------------------

A clinical cohort of 267 colon cancer patients was analyzed in this retrospective study. After approval of the Danbury Hospital Internal Review Board (DHIRB) and collection of the relevant clinical information, FFPE samples were obtained from colon cancer cases that had been preserved between 2000 and 2008. According to the protocol of the study (DH-17/12) including full de-identification of patient information, DHIRB waived the need of informed consent. FFPE samples were cut to 10 µm thickness and two tissue slices were put into a 1.5 ml tube. To each tube, one milliliter of xylene was added for deparaffinization followed by mixing twice with a high speed vortex for 3 min at room temperature. Total RNA was then automatically extracted with the QIAcube using the miRNeasy FFPE kit (Qiagen, Valencia, CA) following manufacturer\'s protocol. The RNA from SW837 cells was automatically extracted with the QIAcube using the miRNeasy kit (Qiagen, Valencia, CA) following manufacturer\'s protocol. RNA quantity and the quality were assessed by Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Analysis was carried out using the 48.48 dynamic array (Fluidigm Corporation, CA, USA) and a Biomark platform following the manufacturer\'s protocol as previously described [@pone.0101065-Mariani1], [@pone.0101065-Prislei1].

Quantitative fluorescent immunohistochemistry {#s2b}
---------------------------------------------

Quantitative fluorescent immunohistochemistry was performed for protein analysis. Tissue specimens were prepared in a Tissue Micro Array (TMA) format: representative tumor areas were obtained from Formalin Fixed Paraffin Embedded (FFPE) specimens of the primary tumor, and up to three representative replicate 3-mm cores from multiple tumor blocks were taken after review and marking of the hematoxylin and eosin stained slides by board-certified pathologists (SS and PF). In total, 630 cores were taken and distributed over 16 slides from 267 patients. FFPE tissues used as controls of the reaction included normal colon, kidney, liver, brain, breast, lymph nodes, thyroid, skin, tonsil, skeletal muscle and bladder along with breast cancer and non-small cell lung cancer.

TMA slides were deparaffinized in xylene and then rehydrated in sequentially diluted ethanol solutions. Antigen retrieval was conducted by heating the slides in a steamer for 30 minutes in a solution of Tris-EDTA pH 8.0. Endogenous peroxidase activity was blocked by treating the slides in Peroxidazed reagent (Biocare Medical, Concord, CA) for 5 minutes. Non-specific binding was reduced by incubation with Background Sniper (Biocare Medical, Concord, CA) for 10 minutes. Slides were incubated with the primary target antibodies and epithelial and stromal cell mask antibodies diluted in Da Vinci Green antibody diluent (Biocare Medical, Concord, CA) for 1 hour at room temperature. Details of all antibodies used are in [Table S1](#pone.0101065.s001){ref-type="supplementary-material"}. Cyanine 5 (Cy5) directly conjugated to tyramide (Perkin-Elmer, Boston, MA) at 1∶50 dilution was used as the fluorescent detection for all the target antigens.

Statistical Analysis {#s2c}
--------------------

For single dimension analysis, overall survival was calculated from the date of diagnosis to the date of death or date last seen. Medians and life tables were computed using the product-limit estimate by the Kaplan and Meier method, and the Log Rank test was employed only to assess the statistical significance. Multivariate analysis assessed the clinical role of each factor matched with other clinical variables (age, stage, grading, type of tumor, and gender), following Cox proportional hazards model. To simplify the issue of censoring, we remove the patients who were censored within 3 years and transformed the survival data into binary response, either aggressive or non-aggressive. For each factor proven to be significant in multivariate analysis (p-value \<0.05), the area under the curve (AUC) in the receiver operating characteristic (ROC) curve was utilized to assess discriminatory power.

For multidimensional analysis, the dataset was randomly divided into training and testing subsets, with 125 cases in each subset. Multiple biomarkers were combined to yield a diagnostic score that was used as a predictor of outcome. To generate the score, we first used sliced inverse regression [@pone.0101065-Li1], [@pone.0101065-Li2] to do the sufficient dimension reduction whereby no information about the conditional distribution of outcome was lost during the dimension reduction. Next, a scalar diagnostic score was computed from the lower dimensional data generated in the first step by likelihood ratio statistic which has been proven to be optimal among all possible functions of multiple markers for binary disease outcomes [@pone.0101065-Pfeiffer1]. This approach enabled utilization of information from multiple markers simultaneously without the need to make assumptions concerning the distributions of the markers. Cox and Kaplan-Meier models were employed to evaluate the statistical significance of multidimensional biomarkers in multivariate analysis as described above.

Results {#s3}
=======

Expression Analysis of microRNA {#s3a}
-------------------------------

The main clinical parameters of the 267 CRC patients enrolled in this retrospective analysis are illustrated in [Table 1](#pone-0101065-t001){ref-type="table"}. All the specimens were collected at the first surgery before any treatment. As anticipated the most important clinical factor to predict outcome was the stage of the disease. For patients at stage IV the progression was fast with a median survival rate of 11 months, while for patients at earlier stages the outcome was better ([Fig. 1](#pone-0101065-g001){ref-type="fig"}). All the patients were then treated with the best available care and this study will focus on pure prognostic predictors and not to predictors of response to specific treatments. As a first step, we screened a series of 33 microRNAs to identify potential predictors of outcome in multivariate analysis including age and stage in the Cox model. MicroRNAs were chosen according to the number of citations in Pubmed using as keywords the terms "colorectal cancer" and "microRNA". Ten microRNAs (MiR-532-3p, Mir-200a, Mir-17, Mir-106a, MiR-193a-5p, MiR-145, MiR-375, Mir-29a, MiR-18a and Mir-200b) were statistically significant with values of range risk ratio (RR) less than 1 for each, meaning that high expression was related to a good outcome ([Table 2](#pone-0101065-t002){ref-type="table"}). To further support the results of Cox analysis, data were also assessed using the Kaplan-Meier method. Five quintile cutoffs (25, 33, 50, 67 and 75) were used to stratify patients for high and low expression of each microRNA and log-rank test served to detect if differences in the outcome were significant. The quintile cutoff providing the lowest p-value at the log-rank test was used as discriminator ([Table 2](#pone-0101065-t002){ref-type="table"}). Seven microRNAs (Mir-200a, Mir-17, Mir-106a, MiR-375, Mir-29a, MiR-18a and Mir-200b) were confirmed to be significant using the Kaplan-Meier method and the corresponding plots are shown in [Fig. 2](#pone-0101065-g002){ref-type="fig"}.

![Kaplan-Meier analysis according to stage of the clinical group of 267 patients enrolled in this retrospective analysis.\
In red stage I--II patients (n = 176), in green stage III patients (n = 82) and in blue stage IV (n = 8).](pone.0101065.g001){#pone-0101065-g001}

![Kaplan-Maier analysis of 267 patients according to the analysis of Mir-200a, Mir-17, Mir-106a, MiR-375, Mir-29a, MiR-18a and Mir-200b expression.\
Kaplan-Maier analysis was performed dividing the patients as high (green) and low (red) setting. Survival time scale is in months. All the differences were significant and p-values are reported in [Table 2](#pone-0101065-t002){ref-type="table"} (Log-rank test).](pone.0101065.g002){#pone-0101065-g002}

10.1371/journal.pone.0101065.t001

###### Distribution of clinico-pathological characteristics of patients.

![](pone.0101065.t001){#pone-0101065-t001-1}

  Characteristics            All Cases (%)   Training Set (%)   Testing Set (%)   p-value[\*](#nt101){ref-type="table-fn"}
  ------------------------- --------------- ------------------ ----------------- ------------------------------------------
  Number                          267              125                125                          0.9469
  Age, yrs Median (range)     70 (22--96)      72 (22--96)        70 (25--95)    
  AJCC Stage                                                                     
  I--II                       176 (65.9)        82 (65.6)          80 (64.0)                       0.8947
  III--IV                      91 (34.1)        43 (34.4)          45 (36.0)     
  Gender                                                                         
  Male                        122 (45.6)        55 (44.0)          59 (47.2)                       0.7033
  Female                      145 (54.3)        70 (56.0)          66 (52.8)     
  Histotype                                                                      
  Adenocarcinoma              243 (91.0)        114 (91.2)        115 (92.0)                       0.9114
  Mucinous                     24 (9.0)          11 (8.8)          10 (8.0)      
  Grade                                                                          
  G1-2                        212 (78.2)        99 (79.2)         101 (80.8)                       0.6091
  G3                           31 (20.9)        18 (14.4)          13 (10.4)     
  N/A                          24 (3.8)          8 (6.4)           11 (8.8)      

\*testing the difference between training and testing set.

10.1371/journal.pone.0101065.t002

###### Results of microRNA expression analysis in the clinical setting of 267 patients with multivariate Cox and Kaplan-Meier method.

![](pone.0101065.t002){#pone-0101065-t002-2}

                 P-value from KM   P-value from Cox   Range risk ratio   Range risk ratio lower limit   Range risk ratio upper limit
  ------------- ----------------- ------------------ ------------------ ------------------------------ ------------------------------
  MiR-532-3p        0.064771           0.008339           0.094842                 0.01648                        0.545822
  Mir-200a           0.0029            0.010557           0.077561                 0.010928                       0.550463
  Mir-17            0.019042           0.011139           0.079489                 0.011251                       0.561619
  Mir-106a          0.020048           0.015244           0.099816                 0.015518                       0.642047
  MiR-193a-5p       0.071498           0.016423           0.108225                  0.0176                        0.665506
  MiR-145           0.107096           0.019985           0.193244                 0.048386                       0.771785
  MiR-375           0.000434           0.020366           0.21165                  0.056987                       0.786067
  Mir-29a           0.001772           0.024357           0.135351                 0.023734                       0.771891
  MiR-18a           0.020165           0.027317           0.224383                 0.059514                       0.845988
  Mir-200b           0.02183           0.047943           0.144104                 0.021133                       0.98261
  Mir-200c          0.015671           0.053802           0.193341                 0.03639                        1.027235
  Mir-429           0.009123           0.057033           0.180053                 0.030799                       1.052607
  Let-7c            0.122339           0.064338           0.218802                 0.043733                       1.094688
  Mir-126           0.013457           0.07168            0.198886                 0.034305                       1.15305
  Mir-92a           0.015478           0.088624           0.311977                 0.081623                       1.192433
  MiR-128           0.074133           0.091335           0.322118                 0.086476                       1.199867
  MiR-18b           0.057048           0.093705           0.350199                 0.102678                       1.194406
  Mir-141           0.030167           0.100176           0.252985                 0.049144                       1.302326
  Mir-27a            0.03627           0.103385           0.259099                 0.051005                       1.316174
  Let-7g             0.11726           0.104305           0.295949                 0.068104                       1.286059
  Mir-221           0.063595           0.119559           0.322513                 0.077581                       1.340726
  Mir-21            0.103007           0.13283            0.341332                 0.084031                       1.386486
  MiR-320           0.005064           0.155964           0.299032                 0.056422                       1.584841
  MiR-642           0.039954           0.185248           0.280021                 0.042591                       1.841022
  Mir-34a           0.042544           0.237098           0.395142                 0.084772                       1.84185
  Let-7e             0.03418           0.328038           0.514886                 0.136147                       1.947215
  Mir-20a           0.321134           0.331775           0.509387                 0.130451                       1.989068
  MiR-328            0.02598           0.383902           0.551185                 0.144202                       2.106798
  Mir-31            0.343731           0.507135           0.570242                 0.108455                       2.998244
  Mir-183            0.31913           0.572282            0.5731                  0.083001                       3.95708
  MiR-30c           0.291601           0.882707           0.893081                 0.198839                       4.011246
  MiR-125b           0.12562           0.941408           0.947918                 0.227684                       3.946476
  Mir-203           0.033555           0.954696           0.959546                 0.230859                       3.988278

Expression Analysis of genes {#s3b}
----------------------------

Nanofluidic technology offers the advantage of allowing analysis of microRNAs and their target genes (targetome) in the same RNA sample due to the low volume of each individual qPCR analysis. To perform this analysis, we employed multiple software applications ([www.miRbase.org](http://www.miRbase.org))[@pone.0101065-Kozomara1] to prepare a list of genes that might be targetable by the 33 microRNAs investigated in this study. The list was prioritized according to a functional network obtained with the DAVID software (<http://david.abcc.ncifcrf.gov>) [@pone.0101065-Huangda1] in order to enrich the pool with actionable targets and master regulators of gene expression and apoptosis. After an initial analysis of 180 candidates, we focused on 79 genes whose expression was detectable in a large number of CRC cancer patients. Six genes (MID1, INHBA, OSBPL3, BGN, DICER1 and FAP) were predictors in univariate analysis (data not shown), but only MID1 remained significant after multivariate correction and Kaplan-Meier analysis ([Table 3](#pone-0101065-t003){ref-type="table"} and [Fig. 3](#pone-0101065-g003){ref-type="fig"}). As a second measure to possibly increase the number of candidate genes, we analyzed the public dataset GSE14333 reporting transcriptome analysis of 290 CRC cancer patients [@pone.0101065-Jorissen1]. For each individual gene, data were analyzed and computed in a multivariate Cox model as described above ([Table 4](#pone-0101065-t004){ref-type="table"}). Predictive capability was confirmed by Kaplan-Maier analysis using a multiple procedure of quintile selection for the cutoff as described above. The 45 genes with the lowest p-values in multivariate analysis were assessed in our platform of nanofluidic gene expression. Only 3 out of 45 (7%) genes were confirmed as predictors of outcome in both GSE14333 and our clinical setting in multivariate Cox regression and Kaplan-Meier analysis (ANO1, KANK4 and IGFBP3, [Table 4](#pone-0101065-t004){ref-type="table"} and [Fig. 3](#pone-0101065-g003){ref-type="fig"}).

![Kaplan-Maier analysis of 267 patients according to the analysis of MID1, ANO1, KANK4 and IGFBP3 expression.\
Kaplan-Maier analysis was performed dividing the patients as high (green) and low (red) setting. Survival time scale is in months. All the differences were significant and p-values are reported in [Table 3](#pone-0101065-t003){ref-type="table"} (Log-rank test).](pone.0101065.g003){#pone-0101065-g003}

10.1371/journal.pone.0101065.t003

###### Results of gene expression analysis in the clinical setting of 267 patients with multivariate Cox and Kaplan-Meier method.

![](pone.0101065.t003){#pone-0101065-t003-3}

              P-value from KM   P-value from Cox   Range risk ratio   Range risk ratio lower limit   Range risk ratio upper limit
  ---------- ----------------- ------------------ ------------------ ------------------------------ ------------------------------
  ANO1           0.000455           0.001999           251.7049                 7.554459                       8386.487
  MID1           0.022369           0.00219            0.061488                 0.010323                       0.366259
  KANK4           0.00051           0.014574           29.03691                 1.946079                       433.2518
  IGFBP3         0.000968           0.021595           14.17555                 1.476178                       136.1259
  KLF6           0.239788           0.02687            0.130799                 0.021595                       0.792224
  GLI3           0.114457           0.038389           0.115389                 0.014944                       0.890962
  SMCR7L         0.037868           0.04224            9.413194                 1.081742                       81.91252
  NEK6           0.066407           0.050178           133.963                  0.996207                       18014.43
  NAT2           0.356728           0.065965           7.387218                 0.876405                       62.26683
  PBX3           0.140048           0.072855           0.076392                 0.004598                       1.26913
  ANGPT2         0.000343           0.073683           21.83904                 0.744166                       640.9105
  AIMP2          0.431665           0.07928            16.0743                  0.722844                       357.4535
  OSBPL3         8.41E-05           0.08083            4.974909                 0.821414                       30.13061
  ATXN1          0.020848           0.102364           8.834232                 0.646996                       120.6247
  TUBB3          0.019182           0.106898           3.208144                 0.777738                       13.2335
  TPBG           0.009543           0.109652           3.902565                 0.735954                       20.69425
  IGF1R          0.134023           0.110324           9.739804                 0.595836                       159.2113
  EZR            0.016156           0.117108           17.77504                 0.485969                       650.1487
  SAV1           0.011384           0.118547           14.03151                 0.509015                       386.7929
  AR             0.348534           0.121365           0.161848                 0.01616                        1.621013
  RAI14           0.00433           0.131537           3.122865                 0.710897                       13.71828
  CXCR4           0.05891           0.140109           0.269459                 0.047199                       1.53833
  UST            0.013135           0.140332           7.706586                 0.510569                       116.324
  INHBA          0.002297           0.145151           3.199909                 0.669214                       15.30066
  CCL5            0.07661           0.146705           0.218204                 0.027924                       1.705063
  STC1           0.047976           0.154726           11.71039                 0.395198                       346.9982
  CALU           0.540614           0.173061           0.215761                 0.02376                        1.959315
  CD109          0.159253           0.178425           5.255192                 0.46883                        58.90633
  DICER1         0.166057           0.19096            0.255369                 0.033012                       1.975454
  HIF1A          0.779411           0.208162           0.362001                 0.074392                       1.76154
  MKI67          0.007381           0.224242           3.396451                 0.472755                       24.40137
  VAV3           0.024025           0.224528           0.47273                  0.141103                       1.583763
  TFAM           0.482992           0.240308           10.34319                 0.209424                       510.8378
  BGN            0.013917           0.24456            2.629649                 0.516015                       13.40088
  UGCG           0.133881           0.245772           18.61169                 0.133532                       2594.106
  PLK2           0.121792           0.271772           7.080799                 0.215788                       232.3469
  CAV2           0.095172           0.276778           2.660236                 0.456206                       15.51242
  BBX            0.374652           0.279638           12.47811                 0.128517                       1211.536
  SNAI1          0.183131           0.282896           0.363617                 0.057377                       2.304384
  MCL1           0.231297           0.283847           0.295541                 0.031804                       2.746347
  COX7A2L        0.122784           0.285949           0.277405                 0.026316                       2.924187
  CEP170         0.018982           0.299886           4.728032                 0.250678                       89.17529
  CCND1          0.171718           0.300918           3.251198                 0.348254                       30.35228
  COMMD2         0.077355           0.303629           5.395563                 0.217408                       133.9053
  ADAMTS5        0.123317           0.305862           2.314392                 0.464361                        11.535
  ESR2           0.153752           0.311968           2.66113                  0.399116                       17.74326
  KLF12          0.465026           0.319069           2.64606                  0.390215                        17.943
  CCL2           0.441674           0.319525           0.438755                 0.086651                       2.22162
  EPAS1          0.490625           0.331663           0.418505                 0.072098                       2.429288
  RTN2           0.249843           0.334748           2.735875                 0.353963                       21.14633
  CHST13         0.039054           0.336699           2.876949                 0.33316                        24.84341
  PIM1           0.105052           0.367117           3.552454                 0.226011                       55.83778
  PPP2CA          0.19979           0.373204           0.317213                 0.025341                       3.970806
  CLOCK          0.209762           0.374067           0.492709                 0.103457                       2.346506
  FAM84A         0.107645           0.37997            0.496851                 0.104249                       2.367992
  TM4SF1         0.158023           0.392541           3.496384                 0.198371                       61.62552
  CAMK2D         0.703007           0.396634           1.968245                 0.411242                       9.420213
  HIPK1          0.368779           0.397418           0.322743                 0.023514                       4.429794
  KLF5           0.089271           0.408022           0.523601                 0.113069                       2.42469
  PTEN           0.554417           0.413923           0.412612                 0.049346                       3.450134
  MYOF           0.275264           0.417654           5.561907                 0.087722                       352.6461
  PNRC1          0.318134           0.420618           3.398165                 0.173127                       66.69977
  IGF2R          0.096886           0.429115           2.60505                  0.242724                       27.95882
  HGF            0.003672           0.429973           2.099431                 0.332818                       13.24333
  CDKN1A         0.059386           0.430643           0.388964                 0.037156                       4.071878
  TGFB1          0.006336           0.446801           2.421279                 0.248095                       23.63038
  KDR             0.18116           0.449974           1.72842                  0.417918                       7.14838
  EPHA3          0.567195           0.472304           0.55043                  0.108045                       2.804128
  CFTR           0.384598           0.47535            2.360475                 0.223261                       24.95658
  ARNT2           0.06533           0.481856           0.413958                 0.035442                       4.834986
  MITF           0.110527           0.487799           1.829958                 0.331946                       10.08821
  AHNAK2         0.188641           0.495026           1.774388                 0.341724                       9.213451
  KLF7           0.049811           0.506272           1.612536                 0.39409                        6.598172
  JAK2           0.394445           0.516395           0.591344                 0.120979                       2.890488
  SOX2           0.150192           0.541916           0.530877                 0.069385                       4.061828
  MAPRE1         0.357987           0.543075           0.557944                 0.085098                       3.658149
  CDH1            0.03582           0.552333           1.615003                 0.332349                       7.847868
  IGSF5          0.019559           0.555833           1.679289                 0.29926                        9.423273
  ANTXR2         0.546413           0.565429           3.671851                 0.043523                       309.7803
  PLK1           0.416995           0.572943           0.671878                 0.168582                       2.677758
  MECP2          0.462499           0.581138           0.626129                 0.118665                       3.303723
  VAMP2          0.161211           0.58226            0.628316                 0.119973                       3.290569
  COL1A1          0.02623           0.584364           0.529685                 0.054348                       5.162451
  FES            0.382467           0.593556           1.591399                 0.288902                       8.766134
  PTK2           0.060876           0.601408           1.649351                 0.25232                        10.78138
  BCL2           0.338186           0.610589           0.626785                 0.103814                       3.784251
  HOXB5           0.27284           0.62191            1.486459                 0.307571                       7.183917
  CYP39A1        0.486591           0.642143           1.671365                 0.191529                       14.58506
  CDX2           0.002486           0.683233           0.651889                 0.083486                       5.090169
  PDGFRB         0.042645           0.69718            1.42049                  0.242459                       8.322194
  CD59           0.005198           0.700335           1.635662                 0.133489                       20.04205
  EPHB2          0.042245           0.744099           0.655446                 0.051878                       8.281188
  FAM1738        0.112702           0.744395           1.849962                 0.045828                       74.67826
  SHMT2          0.040828           0.745961           0.73874                  0.118273                       4.614223
  SLC12A2        0.434188           0.771848           0.776719                 0.140768                       4.285722
  HOXB7          0.195627           0.788445           0.798834                 0.154871                       4.120429
  PBK            0.445747           0.790426           0.821722                 0.193118                       3.496454
  DUSP10          0.13842           0.794739           1.669082                 0.03519                        79.16626
  CISH           0.090655           0.810002           0.754679                 0.076079                       7.486208
  FAP            0.030751           0.811833           1.191001                 0.282441                       5.022236
  MAFF           0.255153           0.814144           0.748927                 0.067236                       8.342135
  MET             0.13437           0.823224           1.374103                 0.084554                       22.33087
  CHEK1          0.163926           0.825053           0.822722                 0.145827                       4.641614
  ESR1           0.056936           0.846116            1.3123                  0.084339                       20.41915
  CDX1           0.010579           0.848595           1.30181                  0.086808                       19.52242
  ADM            0.262582           0.853341           1.156516                 0.247503                       5.40409
  HECTD2         0.353439           0.855316           0.860183                 0.170415                       4.341829
  PPARGC1B        0.37968           0.855611           1.222648                 0.14027                        10.65707
  LDLR           0.355447           0.858784           1.222084                 0.134155                       11.13256
  HIC2           0.176202           0.862587           0.815525                 0.081015                       8.209401
  CHEK2          0.155676           0.866904           1.172525                 0.182286                       7.542064
  AXL            0.039057           0.882521           1.167514                 0.149675                       9.107027
  SRC            0.503974           0.883268           0.895666                 0.205758                       3.898842
  FGFR1          0.416422           0.892855           0.896111                 0.181618                       4.421444
  CXCL10         0.090745           0.898925           0.868597                 0.098801                       7.636207
  ETS2           0.135175           0.904279           0.80061                  0.021349                       30.02398
  KIF11          0.243986           0.91388            0.918496                 0.196749                       4.287873
  ROCK1          0.302625           0.915522           1.123317                 0.131032                       9.630014
  DROSHA          0.25995           0.924716           1.086434                 0.194645                       6.064063
  JAK1           0.113129           0.930365           0.905077                 0.096647                       8.47581
  ERBB2          0.302875           0.962123           1.048409                 0.14901                        7.376446
  CTNNB1         0.099735           0.963275           1.03343                  0.254908                       4.18966
  GBP1           0.040014           0.969138           1.043144                 0.122758                       8.864152
  SLITRK4        0.238082           0.973046           0.978316                 0.274291                       3.489367

10.1371/journal.pone.0101065.t004

###### Results of gene expression analysis in the public dataset GSE14333 with multivariate Cox and Kaplan-Meier method.
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  Probe              Gene     P-value from KM   P-value from Cox   Range risk ratio   Range risk ratio lower limit   Range risk ratio upper limit
  --------------- ---------- ----------------- ------------------ ------------------ ------------------------------ ------------------------------
  229357_at        ADAMTS5       6.04E-06           0.000201           34.0864                  5.305339                       219.0025
  235368_at        ADAMTS5       1.32E-06           8.75E-05           42.64678                 6.539883                       278.101
  219935_at        ADAMTS5       8.92E-05           0.000265           22.25267                 4.200208                       117.8945
  1558636_s\_at    ADAMTS5       0.001966           0.005793           100.589                  3.802689                       2660.788
  220726_at         AHNAK2        0.26889           0.690171           0.697388                 0.118539                       4.102851
  1558378_a\_at     AHNAK2       0.000362           0.00308            27.08616                 3.047499                       240.7416
  212992_at         AHNAK2       1.55E-06           3.46E-05           483.5156                 25.93489                       9014.392
  209971_x\_at      AIMP2        0.000178           0.000173           0.056117                 0.01248                        0.252328
  202138_x\_at      AIMP2        0.000483           5.44E-05            0.0415                  0.00885                        0.194598
  209972_s\_at      AIMP2        0.012259           0.457615           0.415432                 0.040911                       4.218525
  205572_at         ANGPT2       0.007138           0.027838           11.73135                 1.307621                       105.248
  236034_at         ANGPT2       0.003749           0.000137           102.5228                 9.496737                       1106.794
  211148_s\_at      ANGPT2       0.000103           0.066738           26.07117                 0.798486                       851.2436
  237261_at         ANGPT2       0.032343           0.153008           12.34905                 0.392984                       388.0543
  1555269_a\_at      ANO1        0.005692           0.02366            23.37811                 1.52436                        358.5346
  218804_at          ANO1        0.001514           0.000249           88.27612                 8.031295                       970.2886
  1555536_at        ANTXR2       0.165872           0.448339           1.992017                 0.33543                        11.82999
  225524_at         ANTXR2       0.002183           0.00047            44.01017                 5.278853                       366.916
  228573_at         ANTXR2       0.005047           0.000316           19.32602                 3.857263                       96.82903
  213015_at          BBX         0.003728           0.006287           20.99437                 2.364569                       186.4033
  1557239_at         BBX         0.291266           0.980533           1.036403                 0.058639                       18.31775
  223134_at          BBX         6.95E-05           0.00274            30.21056                 3.248415                       280.9611
  226331_at          BBX         2.81E-05           8.81E-07           359.268                  34.41053                       3750.987
  213016_at          BBX         0.004471           0.000586           102.7534                 7.326352                       1441.135
  223135_s\_at       BBX         6.36E-08           1.22E-05           45.64845                 8.239986                       252.8865
  232008_s\_at       BBX         0.000531           9.24E-05           102.4825                 10.06176                       1043.82
  1557240_a\_at      BBX         0.169963           0.299311           2.43368                  0.453789                       13.05188
  213426_s\_at       CAV2        0.188766           0.031867           7.132542                 1.18575                        42.90378
  203324_s\_at       CAV2        3.97E-07           4.18E-05           41.99252                 7.026959                       250.9438
  203323_at          CAV2        1.60E-09           2.04E-06           77.00721                 12.82191                       462.4983
  229900_at         CD109        0.041603           0.004916           26.16536                 2.689981                       254.5096
  226545_at         CD109        0.000325           0.00023            20.46414                 4.105505                       102.0048
  200984_s\_at       CD59        0.000362           0.000149           55.54448                 6.96658                        442.8556
  200983_x\_at       CD59        1.14E-06           3.41E-05           70.30158                 9.407096                       525.3813
  200985_s\_at       CD59        9.51E-06           3.67E-05           52.14801                 7.975754                       340.9602
  212463_at          CD59        6.84E-07           1.22E-06           175.8647                 21.78629                       1419.626
  228748_at          CD59        0.004633           0.041237           7.88942                  1.085611                       57.33449
  206430_at          CDX1        6.36E-07           4.45E-05           0.030374                 0.005675                       0.162561
  206387_at          CDX2         0.0014            3.67E-05           0.073955                 0.021472                       0.254721
  231606_at          CDX2        0.000568           0.095068           0.303118                 0.074635                       1.231068
  212746_s\_at      CEP170       0.000299           0.009884           23.82942                 2.142353                       265.055
  207719_x\_at      CEP170       0.000131           6.49E-05           31.19191                 5.766271                       168.7287
  234702_x\_at       CFTR         0.01694           0.27293            0.461545                 0.115856                       1.838699
  215703_at          CFTR        0.037325           1.37E-05           0.053111                 0.014147                       0.199386
  217026_at          CFTR        0.385981           0.252799           0.168605                 0.007976                       3.563921
  215702_s\_at       CFTR        0.012329           0.000782           0.02279                  0.002509                       0.206981
  234706_x\_at       CFTR        0.371555           0.578887           0.511618                 0.047986                       5.454732
  205043_at          CFTR        0.021692           3.17E-05           0.065349                 0.018078                       0.236224
  239647_at         CHST13       0.000319           3.61E-05           0.07416                  0.021584                       0.254811
  242503_at         CHST13       0.246465           0.263741           0.463753                 0.120515                       1.784564
  223377_x\_at       CISH         0.01124           0.030594           0.153875                 0.02821                        0.839335
  223961_s\_at       CISH        4.08E-05           5.85E-05           0.033215                 0.006312                       0.174775
  221223_x\_at       CISH        0.002772           0.001846           0.036573                 0.004558                       0.293441
  226910_at         COMMD2       0.000633           0.000126           37.40157                 5.872115                       238.2237
  223491_at         COMMD2       3.60E-05           0.019365           10.47272                 1.462487                       74.99413
  221563_at         DUSP10       5.91E-05           0.001099           37.05756                 4.233756                       324.3604
  215501_s\_at      DUSP10       1.84E-05           0.000388           26.5064                  4.335402                       162.0586
  209588_at         EPHB2         0.00033           9.89E-05           0.05185                  0.011687                       0.230028
  209589_s\_at      EPHB2        0.010517           0.00193            0.082811                 0.017148                       0.399908
  211165_x\_at      EPHB2        2.20E-05           0.000149           0.046433                  0.0095                        0.226942
  210651_s\_at      EPHB2        0.027564           0.000968           0.060346                 0.011386                       0.319845
  234158_at         EPHB2        0.031839           0.169435           0.412742                 0.116806                       1.45845
  233699_at         EPHB2        0.231256           0.453665           1.688996                 0.428775                       6.653159
  222303_at          ETS2        0.006806           0.005887           0.114387                 0.024448                       0.535198
  201328_at          ETS2        0.000411           8.08E-05           0.081369                 0.023375                       0.283247
  201329_s\_at       ETS2        0.000328           8.38E-05           0.065016                 0.016656                       0.253792
  208621_s\_at       EZR         0.034737           0.097102           7.073765                  0.7013                        71.35055
  217234_s\_at       EZR         0.044295           0.041498           9.910504                 1.092409                       89.90964
  208622_s\_at       EZR         0.000622           0.001303           99.00849                 6.013656                       1630.07
  208623_s\_at       EZR         4.02E-07           2.11E-05           1207.412                 45.89005                       31768.2
  217230_at          EZR         0.174403           0.140414           3.361179                 0.670718                       16.84393
  238645_at          EZR         0.021088           0.042168           11.38081                 1.089858                       118.8439
  215200_x\_at       EZR         0.286994           0.318044           2.823012                 0.368122                       21.64879
  225670_at        FAM173B       2.61E-05           0.000117           0.033282                 0.005894                       0.187931
  225668_at        FAM173B       0.063779           0.343216           0.331004                 0.033645                       3.256445
  234335_s\_at      FAM84A       1.84E-05           2.34E-05           0.021597                 0.003653                       0.127692
  229546_at         FAM84A       0.000894           2.59E-05           0.034042                 0.007048                       0.164431
  225667_s\_at      FAM84A       0.000701           1.19E-05           0.013224                 0.001908                       0.091637
  234331_s\_at      FAM84A       0.000489           3.23E-07           0.010521                 0.001834                       0.06036
  231439_at         FAM84A       0.002881           0.00016            0.043208                 0.008456                       0.220772
  228459_at         FAM84A       0.000124           0.00285            0.104682                 0.023768                       0.461058
  228319_at         FAM84A       0.088904           0.688981           0.609438                 0.053918                       6.888528
  210095_s\_at      IGFBP3        0.00038           0.000122           34.81351                 5.693815                       212.8592
  212143_s\_at      IGFBP3       3.87E-06           6.58E-05           40.75663                 6.598764                       251.7294
  243027_at         IGSF5        0.000113           0.001432           55.30184                 4.691637                       651.8607
  229125_at         KANK4        8.48E-06           0.000276           12.86927                 3.247498                       50.99869
  217173_s\_at       LDLR        0.011169           0.16538            4.576761                 0.533656                       39.25138
  202067_s\_at       LDLR        0.002542           0.120351           14.71872                 0.494593                       438.0182
  202068_s\_at       LDLR        0.002236           0.000255           51.66079                 6.236509                       427.9376
  217103_at          LDLR        0.340416           0.568331           0.54143                  0.065787                       4.456002
  217183_at          LDLR        0.129907           0.480234           1.708543                 0.386148                       7.559592
  217005_at          LDLR        0.074924           0.228696           2.675823                 0.538828                       13.28814
  205193_at          MAFF        0.000158           0.000102           44.54421                 6.562634                       302.3461
  211864_s\_at       MYOF        1.04E-05           0.000138           62.98781                 7.483162                       530.1855
  201798_s\_at       MYOF        0.000208           2.47E-05           188.5189                 16.51764                       2151.602
  217518_at          MYOF        0.020004           0.166863           4.972052                 0.511631                       48.31859
  206797_at          NAT2        0.000112           2.13E-05           0.062607                 0.017448                       0.224656
  201939_at          PLK2        0.003791           7.69E-05           14.06108                 3.792438                       52.13371
  209034_at         PNRC1        1.45E-05           4.87E-05           31.43427                 5.954339                       165.9484
  1555282_a\_at    PPARGC1B      0.060267           0.352001           0.505394                 0.120092                       2.126897
  1553639_a\_at    PPARGC1B      3.01E-06           2.18E-05           0.03799                  0.008394                       0.171939
  1563943_at       PPARGC1B      0.458245           0.985653           1.014717                 0.206439                       4.98768
  202052_s\_at      RAI14        5.41E-07           0.000287           2081.501                 33.49958                       129334.4
  204217_s\_at       RTN2        0.000905           0.007263           165.478                  3.970497                       6896.612
  222573_s\_at       SAV1        0.002144           0.027685           13.52864                 1.331125                       137.4957
  218276_s\_at       SAV1        1.68E-06           4.00E-05           39.62951                 6.846883                       229.3742
  234491_s\_at       SAV1        0.023935           0.012655           15.70887                 1.802495                       136.9039
  236606_at          SAV1        0.028297           0.161562           149.8623                 0.134718                       166709.5
  204404_at        SLC12A2       3.73E-06           0.000236           0.05294                  0.011053                       0.253562
  225835_at        SLC12A2       0.001286           0.007522           0.111752                 0.022405                       0.557401
  232636_at        SLITRK4       8.73E-06           0.000342           1081.219                 23.6349                        49462.24
  204596_s\_at       STC1        0.001429           0.002766           128.3408                 5.339502                       3084.814
  204595_s\_at       STC1        9.53E-06           0.000234           26.79181                  4.6472                        154.4589
  230746_s\_at       STC1        0.000866           0.000953           17.63863                 3.214301                       96.79288
  204597_x\_at       STC1        2.33E-06           0.002335           76.65634                 4.689406                       1253.079
  238443_at          TFAM        0.059819           0.225228           0.371229                 0.074838                       1.841456
  203177_x\_at       TFAM        1.71E-05           0.000113           0.022829                 0.00335                        0.155556
  208541_x\_at       TFAM        0.002744           0.054875           0.216047                 0.045206                       1.032524
  203176_s\_at       TFAM        0.000342           0.003043           0.115476                 0.027697                       0.481457
  238168_at         TM4SF1       0.030768           0.014898           614.9803                 3.498935                       108090.2
  209387_s\_at      TM4SF1       2.56E-08           2.02E-06           800.6651                 50.79976                       12619.44
  215034_s\_at      TM4SF1       3.95E-07           1.61E-07           1067.398                 78.60081                       14495.26
  209386_at         TM4SF1       5.87E-10           8.06E-08           1440.194                 101.0956                       20516.8
  215033_at         TM4SF1       0.000849           0.024728           76.44376                 1.736114                       3365.936
  203476_at          TPBG        6.74E-05           0.000102           53.32757                 7.179862                       396.0842
  224967_at          UGCG        0.000167           0.000189           25.07686                 4.619337                       136.1341
  204881_s\_at       UGCG        0.030888           0.25574            2.664385                 0.491631                       14.43957
  221765_at          UGCG        6.94E-05           0.01459            18.46403                 1.778815                       191.6559
  205138_s\_at       UST         0.039899           0.095085           3.788817                 0.792891                       18.10481
  205139_s\_at       UST         0.000152           8.32E-05           39.8298                  6.355425                       249.6155
  214792_x\_at      VAMP2         0.00019           0.000615           45.85393                 5.13567                        409.4078
  201556_s\_at      VAMP2         0.00036           0.000231           51.11359                 6.295788                       414.9757
  201557_at         VAMP2        0.001365           0.001694           1058.693                 13.68399                       81908.26

Expression Analysis of proteins {#s3c}
-------------------------------

To conduct analysis at the protein level, we chose 9 factors (TUBB3, ELAVL1, OSBPL3, IGFBP3, ANO1, HGF, GLI3, PPP2CA and ARNT2). TMAs were prepared from the same paraffin blocks used for gene and microRNA analysis. Triplicate cores of each case were included in the TMAs to capture clonal heterogeneity, and each TMA was analyzed in triplicate by multiplexed, quantitative fluorescent immunohistochemistry. Nuclei were stained with DAPI (blue channel), and stromal and epithelial cells were stained with anti-vimentin (green channel) and anti-cytokeratin (yellow channel), respectively. Antigens of interest were acquired in the red channel, and a representative image of the analysis for IGFBP3 and ANO1 is shown in [Fig. 4A](#pone-0101065-g004){ref-type="fig"}. For each protein, expression was quantified with AQUA software which utilizes an unsupervised algorithm to quantify expression in defined subcellular compartments or "masks". In our study, we selected four masks: tumor (cytokeratin+), stromal (vimentin+), tumor nuclei (DAPI+/cytokeratin+) and tumor cytoplasm (DAPI-/cytokeratin+). For each 3 mm core, at least three electronic subsegments (histospots) were analyzed. Because of replicate analysis, we collected up to 18 AQUA scores for each patient which were then averaged. GLI3, ARNT2 and HGF showed predominantly nuclear staining in some cancer cells, while in others, the staining was predominantly cytoplasmic. To exploit this phenomenon, an index was created by dividing the nuclear over the cytoplasmic expression. A value \>1 was typical of a strong nuclear staining, while a value \<1 indicated a predominantly cytoplasmic pattern of expression. Expression of all proteins and the index were analyzed with multivariate Cox regression analysis. Only expression of ANO1 (in cancer cells and in the nuclei of cancer cells) was significant in multivariate analysis ([Table 5](#pone-0101065-t005){ref-type="table"} and [Fig. 4B](#pone-0101065-g004){ref-type="fig"}).

![Representative quantitative immunofluorescence for IGFBP3 (left column) and ANO1 (right column).\
A: From top to bottom the following signals are represented: antigen of interest (red channel), cell nuclei (DAPI), tumor cells (cytokeratin), stromal cells (vimentin) and merged image. B: Kaplan-Maier analysis of 267 patients according to the expression of AQUA scores of ANO1 inside the tumor mask (ANO1_AQUA) and in the nucleus of cancer cells (ANO1_Nuclear_AQUA). Kaplan-Maier analysis was performed dividing the patients as high (green) and low (red) setting. All the differences were significant and p-values are reported in [Table 5](#pone-0101065-t005){ref-type="table"} (Log-rank test).](pone.0101065.g004){#pone-0101065-g004}
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###### Results of quantitative fluorescent immunohistochemistry quantified with AQUA in the clinical setting of 267 patients with multivariate Cox and Kaplan-Meier method.

![](pone.0101065.t005){#pone-0101065-t005-5}

                         P-value from KM   P-value from Cox   Range risk ratio   Range risk ratio lower limit   Range risk ratio upper limit
  --------------------- ----------------- ------------------ ------------------ ------------------------------ ------------------------------
  ANO1_Nuclear_AQUA         0.019325            0.0163            5.334706                 1.360938                       20.91138
  ANO1_AQUA                 0.000898           0.047176           3.933242                 1.017225                       15.20842
  ANO1_Cyto_AQUA            0.000466           0.064055           3.455312                 0.930134                       12.83598
  OSBPL3_Cyto.AQUA          0.123325           0.07897            0.188465                 0.029282                       1.213009
  OSBPL3_Nuclear_AQUA       0.109894           0.080147           0.19641                  0.031728                       1.21585
  ARNT2_Cyto_AQUA           0.167487           0.140698           3.728865                 0.647353                       21.47889
  ANO1_Stromal_AQUA         0.196194           0.168063           2.759558                 0.651671                       11.68558
  ARNT2_Nuclear_AQUA        0.216922           0.190952           3.466272                 0.537979                       22.33368
  HGF_Index                 0.072421           0.256612           0.421516                 0.094756                       1.875095
  IGFBP3_Nuclear_AQUA       0.103525           0.280396           2.469812                 0.478288                       12.75378
  IGFBP3_AQUA                0.03215           0.334276           2.071344                 0.472373                       9.082782
  IGFBP3_Cyto_AQUA          0.022362           0.355887           1.91389                  0.482418                       7.592945
  OSBPL3_AQUA               0.253341           0.414725           3.737845                 0.157242                       88.85318
  IGFBP3_Stroma_AQUA        0.256147           0.43221            1.819391                 0.408595                       8.101375
  Gli3_Cytoplasm_AQUA       0.630287           0.440849           1.603306                 0.482704                        5.3254
  HGF_Cyto_AQUA             0.460081           0.504868           0.586884                 0.122545                       2.810666
  Gli3_Index                0.282345           0.566901           0.656363                 0.155334                       2.773461
  ARNT2_Index               0.419295           0.615751           0.562225                 0.059327                       5.328067
  Gli3_Nuclear_AQUA         0.472219           0.621925           1.339116                 0.419535                       4.274326
  ELAVL1_AQUA               0.185824           0.642386           1.911476                 0.124104                       29.44091
  PPP2CA_AQUA               0.431568           0.706374           0.667826                 0.081745                       5.455859
  TUBB3_Aqua                0.142229           0.752119           1.238951                 0.327804                       4.682667
  HGF_AQUA                  0.244703           0.75816            0.76795                  0.143024                       4.12343
  HGF_Nuclear_AQUA          0.403127           0.790899           0.785888                 0.13239                        4.665154
  ARNT2_AQUA                0.137421           0.793627           1.212292                 0.286559                       5.128612
  Gli3_AQUA                 0.405624           0.813404           0.833907                 0.184549                       3.768124
  TUBB3_Cyto_AQUA           0.253091           0.857207           0.884385                 0.23196                        3.371855
  ELAVL1_Cyto_AQUA          0.375018           0.900491           1.157521                 0.116881                       11.4634
  ELAVL1_Index              0.296773           0.915789           0.90653                  0.147036                       5.58907
  TUBB3_Nuclear_AQUA        0.443265           0.919185           0.947465                 0.334061                       2.68721
  ELAVL1_Nuclear_AQUA       0.037163           0.958367           1.07847                  0.063246                       18.39011

Nuclear and Cyto indicate expression of the antigen in nucleus and cytoplasm, respectively. If no specified expression was assessed inside the cancer cells. Stromal expression refers to vimentin-positive cells. Index was created dividing the nuclear over the cytoplasmic expression.

Calculation of Predictive Accuracy {#s3d}
----------------------------------

We divided the patients into two clinical groups of interest to allow simplification of censored data into a binary response. Those surviving less than three years from diagnosis were labeled as having aggressive disease, while those surviving for greater than three years were considered to have more indolent, non-aggressive disease. Each of the individual factors from the three dimensions above (microRNA, gene or protein) was tested as a predictor of disease aggressiveness using ROC curves with AUC calculation. Although some factors were statistically significant in multivariate analysis, the maximum AUC obtained from any single biomarker in a single dimension was only 0.68 (ADAMTS5). Utilizing such a weak predictor for patient care would be unacceptable as it is inaccurate (either falsely positive or falsely negative) in approximately one third of the cases.

Generation of multidimensional biomarkers {#s3e}
-----------------------------------------

We speculated that, by combining the information from different dimensions (microRNA, gene and protein), we could substantially increase predictive accuracy. However, multidimensionality engenders significant computational complexities and challenges. Whereas in single dimension analysis the number of considered variables in our case is relatively limited at 188, multidimensional analysis of two and three variables yields 17,578 and 1,089,836 combinations, respectively. Controlling for type 1 errors using cross-validation becomes critically important as the number of variables rises. For this reason, after excluding 17 patients due to incomplete data, we randomly assigned the remaining 250 patients to either training or testing set ([Tab. 1](#pone-0101065-t001){ref-type="table"}). As a first step, we randomly chose either two or three variables from all the microRNAs, genes and proteins that we considered. After sufficient dimension reduction, variables were combined into a new diagnostic score, which included all the information of the parental factors. Computation clearly demonstrated that by increasing the amount of data from different dimensions, the calculated AUCs increased in the training set ([Fig. 5A](#pone-0101065-g005){ref-type="fig"}). After computation of all the 1,089,836 multidimensional predictors, we selected the combinations with the highest ranking of AUCs. We then added one additional biomarker at a time, a microRNA, gene or protein, into the existing combinations while considering all possible combinations, and calculated the AUCs again in the training set ([Fig. 5B](#pone-0101065-g005){ref-type="fig"}). This process was repeated until AUCs reached a maximum and failed to increase significantly by adding additional predictors into the existing combinations. These maximums were reached when number of variables inside each combination reached 10 in the training set ([Fig. 5B](#pone-0101065-g005){ref-type="fig"}). Thereafter, we analyzed the top combinations in the testing set and we found 15 multidimensional biomarkers (MB) which showed AUC values \>0.83 in the training and testing set (composition is reported in [Table 6](#pone-0101065-t006){ref-type="table"}, [7](#pone-0101065-t007){ref-type="table"} and [8](#pone-0101065-t008){ref-type="table"}) supporting the notion that multidimensional biomarkers are more accurate than any individual single dimension predictor. From this list, we selected the 4 most accurate multidimensional biomarkers (MB1 to MB4), each with AUCs of approximately 0.9 in both training and test sets ([Fig. 6A](#pone-0101065-g006){ref-type="fig"}). Their composition is graphically depicted in [Fig. 6B](#pone-0101065-g006){ref-type="fig"}. These biomarkers were also outstanding predictors of outcome in Kaplan-Meier analysis ([Fig. 6C](#pone-0101065-g006){ref-type="fig"}).

![Box-whisker plot representing the values of AUC in the training set.\
In the boxplot, from bottom to top, they are Q1-1.5\*IQR, Q1, median, Q3, and Q3+1.5\*Q3 where Q1 is first quartile (25^th^ percentile), Q3 is the third quartile (75^th^ percentile), and IQR is the interquartile (namely, Q3-Q1). In A the analysis is made with a single variable, with all the possible combination of two (n = 17,578) and three variables (n = 1,089,836). In B the analysis is performed by adding one new variable (gene, microRNA or protein) to the previous top combinations.](pone.0101065.g005){#pone-0101065-g005}

![Bar Chart reporting AUC of the top MB obtained in the training and testing set (A).\
Graphical chart of the composition of MB1-4 (B). In blue, green and red protein, genes and microRNA are reported. Kaplan-Maier analysis of the training and testing set according to the expression of the top 4 MB (C). All the differences were highly significant (Log-rank test) and are reported in [Table 7](#pone-0101065-t007){ref-type="table"} and [8](#pone-0101065-t008){ref-type="table"} for training and testing set, respectively.](pone.0101065.g006){#pone-0101065-g006}

10.1371/journal.pone.0101065.t006

###### AUC analysis for the top 15 multidimensional biomarkers in the training and testing set.

![](pone.0101065.t006){#pone-0101065-t006-6}

  AUC Combinations                                                                                      MB   Training     Test
  ---------------------------------------------------------------------------------------------------- ---- ---------- ----------
  DICER1+IGFBP3+Mir−29a+HGF_Index +ADAMTS5+OSBPL3_Cyto_AQUA+ETS2+EPHA3+SHMT2+ESR1                       1    0.91059    0.89881
  ADAMTS5+OSBPL3_Cyto_AQUA+HGF_Index+ESR2+ANGPT2+HGF_Nuclear_AQUA+ARNT2+IGFBP3+Mir−29a+HGF_Cyto_AQUA    2    0.921007   0.871599
  CD109+IGFBP3+Let−7c+CISH+KLF7+CDX1+MITF+ADAMTS5+ANO1+ANTXR2                                           3    0.914251   0.861305
  HOXB7+IGFBP3+Mir−141+HGF_Index+ESR1+ANO1+PLK2+OSBPL3_AQUA+COX7A2L+IGFBP3_Stroma_AQUA                  4    0.865103   0.899916
  HOXB7+IGFBP3+MiR−320+HGF_Index+DROSHA+KLF6+Mir−200a+FGFR1+TM4SF1+Mir−200b                             5    0.916084   0.847826
  IGFBP3+Mir−29a+PNRC1+HGF_Index+CFTR+SRC+KLF5+KIF11+ANO1+CAV2                                          6    0.903652   0.855797
  EZR+Mir−17+HGF_Index+ANO1+IGFBP3_AQUA+OSBPL3_AQUA+Mir−200b+PIM1+ANO1_AQUA+PPP2CA                      7    0.827957   0.930193
  EZR+Mir−200a+HGF_Index+IGFBP3+Mir−17+ESR1+Mir−92a+ERBB2+DUSP10+PLK2                                   8    0.868687   0.881884
  DICER1+IGFBP3+MiR−193a−5p+CDX1+DROSHA+ANTXR2+HGF_Index+KIF11+OSBPL3_Cyto_AQUA+PLK2                    9    0.875868   0.872449
  RAI14+HGF_Index+STC1+MiR−18a+COX7A2L+SOX2+SMCR7L+NAT2+MCL1+ANTXR2                                     10   0.845377   0.88913
  HOXB7+IGFBP3+Mir−141+HGF_Index+ESR1+ANO1+PLK2+OSBPL3_AQUA+COX7A2L                                     11   0.844618   0.885606
  IGFBP3+Mir−29a+PNRC1+HGF_Index+CFTR+SRC+KLF5+KIF11+ANO1                                               12   0.885781   0.843478
  HOXB7+IGFBP3+MiR−320+HGF_Index+DROSHA+KLF6+Mir−200a+FGFR1                                             13   0.862471   0.845652
  DICER1+IGFBP3+Let−7g+CDX1+ANTXR2+ADM+DROSHA+KLF6+TUBB3_Cyto_AQUA+HGF_Cyto_AQUA                        14   0.86748    0.837662
  EZR+Mir17+HGF_Index+ANO1+IGFBP3_AQUA+OSBPL3_AQUA+Mir−200b+PIM1+ANO1_AQUA                              15   0.839687   0.849453

10.1371/journal.pone.0101065.t007

###### KM and Cox information in training set for all the top multidimensional biomarkers.

![](pone.0101065.t007){#pone-0101065-t007-7}

  MB    P-value from KM   P-value from Cox   Range risk ratio   Range risk ratio lower limit   Range risk ratio upper limit
  ---- ----------------- ------------------ ------------------ ------------------------------ ------------------------------
  1        2.00E-07           1.51E-06           653.0181                 46.55881                       9159.011
  2        1.28E-07           3.80E-06           258.9312                 24.54175                       2731.889
  3        1.48E-09           7.80E-07           327.9436                 32.9403                        3264.907
  4        6.92E-08           1.15E-05           331.7012                 24.79851                       4436.787
  5        1.07E-09           1.24E-05           40807.52                 349.2252                       4768423
  6        9.46E-08           2.72E-06           112.5715                 15.63995                       810.2548
  7        1.09E-06           0.000413           195.6531                 10.46789                       3656.91
  8        1.75E-05           2.97E-05           266.2441                 19.35674                       3662.079
  9        9.17E-06           0.000101           192.0735                 13.57356                       2717.948
  10       1.67E-06           6.71E-05           12784.75                 122.3606                       1335805
  11       1.81E-05           5.65E-06           102.7509                 13.90232                       759.4232
  12       7.40E-08           3.94E-06           560.1007                 38.10062                       8233.798
  13       3.96E-08           6.38E-05           32337.23                 199.1264                       5251420
  14       2.69E-05           0.000165           402.8112                 17.78357                       9123.973
  15       0.000179           0.000116           89.50607                 9.105603                       879.8249

10.1371/journal.pone.0101065.t008

###### KM and Cox information in testing set for all the top multidimensional biomarkers.

![](pone.0101065.t008){#pone-0101065-t008-8}

  MB    P-value from KM   P-value from Cox   Range risk ratio   Range risk ratio lower limit   Range risk ratio upper limit
  ---- ----------------- ------------------ ------------------ ------------------------------ ------------------------------
  1        1.08E-07           0.000175           149.4211                 10.9347                        2041.818
  2        8.10E-07           0.000655           135.4344                 8.046889                       2279.45
  3        1.00E-05           2.96E-07           134.664                  20.66007                       877.7509
  4        1.02E-06           0.000173           174.0681                 11.78516                       2571.004
  5        0.000107           0.000499           64.97979                 6.196342                        681.43
  6        1.51E-06           0.000702           75.67874                 6.197425                       924.1375
  7        1.21E-09           6.37E-07           301.1185                 31.85225                       2846.654
  8        2.45E-08           7.39E-06           1150.195                 52.76299                       25073.42
  9        1.17E-06           2.19E-05           165.1841                 15.62799                       1745.956
  10       0.003986           0.008584           33.05786                 2.43376                        449.0262
  11       0.000976           0.000481           171.8073                 9.553675                       3089.673
  12       0.000404           0.003664           16.68279                 2.499333                       111.3559
  13        0.00047           0.002143            657810                  126.8559                       3.41E+09
  14       2.47E-05           2.90E-05           143.1154                 13.97101                       1466.037
  15       0.000149           4.68E-06           647.3492                 40.53591                       10338.02

Discussion {#s4}
==========

CRC cancer remains among the deadliest malignancies. For clinical management, particularly in stage II and III disease, multiple therapeutic options are now available. As observed also in our clinical study the outcome is mostly driven by clinical stage at diagnosis with stage IV patients presenting a severe prognosis. However, even in patients with earlier stages the outcome is not only favorable with a significant relapse rate. Discoveries of effective biomarkers that can guide therapeutic decisions are ambitiously sought in the hopes of achieving the best possible outcomes, minimizing not necessary and toxic procedures. A host of studies have been conducted toward this end [@pone.0101065-Newton1], [@pone.0101065-Hogan1], [@pone.0101065-GonzalezGonzalez1]. The ideal biomarker to drive clinical treatments should be significant in multivariate analysis while having robust predictive accuracy with few false positive and false negative results. Some limited successes have been obtained with regard to the selection of specific therapeutic regimens according to toxicity and efficacy [@pone.0101065-Newton1]. However, most of these promising individual biomarkers have fallen short in clinical trials [@pone.0101065-Tejpar1]. More complex biomarkers have been created, albeit in a single dimension. One 12-gene panel was effective in predicting risk of recurrence and response to treatment in a large clinical study of 1436 patients of stage II and III CRC patients [@pone.0101065-Gray1]. However, later validation studies did not reproduce the same results [@pone.0101065-SanzPamplona1], since the Achilles\' heel of this technology remains the lack of accuracy in independent validation studies. In our study we intend dimension as the nature of the variable, being microRNA, a gene or a protein. We believe that the lack of accuracy should be dependent at least in part from the fact that the 12-gene signature was obtained only in the gene dimension, thus downsizing the possible role that other factors such as microRNA and protein may have in the predictive capability of genes. This past experience prompted us to revisit the way predictive biomarkers are built. Cancer aggressiveness is a complex trait in most of the cases. It is like a multifactorial equation. To make the pattern more complex, such multiple factors are coming from different dimensions such as genes, proteins, DNA sequences and different subset of cells (cancer and stromal). Our idea was centering the prediction on an integrated method of analysis including more dimensions and more factors at the same time. We believe that only an integrated approach can get closer to the solution of a multifactorial equation. The results we present in this study support our hypothesis. In our cohort of CRC patients, we first analyzed a large panel of possible individual predictors coming from each of three single dimensions (microRNA, gene or protein). We were indeed able to identify statistically significant predictors of outcome as determined by multivariate Cox analysis and Kaplan-Meier method. Some of these predictors have not been extensively investigated in CRC to date. As an example, expression of ANO1 (anoctamine 1) was found to be statistically significant at the gene and protein level, re-enforcing recent data coming from analysis of the dataset GSE14333 [@pone.0101065-Jorissen1]. However, AUC of ANO1 in our analysis was not greater than 0.65, meaning that as a driver of clinical decisions, ANO1 would misclassify a consistent number of patients. Thus, statistical significance does not necessarily translate into clinical utility. Failure to recognize this fact can account for much of the disappointment with individual biomarkers derived from a single dimension [@pone.0101065-Srivastava1], [@pone.0101065-SanzPamplona1].

Not satisfied with AUCs below 0.7 and in the hopes of developing more robust predictors, we sought to combine our data in novel ways. In this manuscript, we provide details of a multidimensional platform which combines nanofluidic technology with quantitative fluorescent immunohistochemistry to create biomarkers with AUCs approaching and even exceeding 0.9. While the number of variables that need to be analyzed is immense, this potent toolset can collect multidimensional data at a reasonable reagent cost for FFPE samples (\$0.20 for gene/microRNA analysis, \$0.85 per protein).

Beyond predicting clinical outcome, our assay can highlight molecular drivers of aggressiveness. For example, IGFBP3 appears in all of the four top multidimensional biomarkers. This antigen is well known to researchers in CRC, although conflicting data are present in the literature regarding its effects [@pone.0101065-Georges1]. At the gene expression level in both GSE14333 and our data set, high expression of IGFBP3 was related to poor outcome. This is in keeping with other previous studies [@pone.0101065-Georges1], [@pone.0101065-Kansra1], [@pone.0101065-Baxter1]. The weight of evidence surely implicates this gene as a prominent driver of CRC cancer aggressiveness despite its being at odds with older studies connecting IGFBP3 expression to an anti-proliferative effect on the growth of colon cancer cells (reviewed in [@pone.0101065-Baxter2]).

Only two variables were present in 3 out of the 4 top multidimensional biomarkers: ADAMTS5 and HGF index. ADAMTS5 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. The enzyme encoded by this gene contains two C-terminal TS motifs and functions as aggrecanase to cleave aggrecan, a major proteoglycan of cartilage [@pone.0101065-HeldFeindt1]. As single factor, in the dataset GSE14333, high expression was associated with poor outcome in multiple probes. However, in our analysis, this factor did not show a significant trend in multivariate analysis as single element. Literature on ADAMTS5 in CRC cancer is extremely limited with only one study reporting this gene as one of the most hypermethylated in tumor as compared with the surrounding normal colonic mucosa [@pone.0101065-Kim1]. The other variable, HGF (hepatocyte growth factor) index, represents a pathway that is known to be activated in aggressive CRC. HGF has been extensively investigated as a potential new target (reviewed in [@pone.0101065-Lemos1]). Although HGF expression in immunoperoxidase staining appears with a clear cytoplasmic pattern in CRC cancer cells [@pone.0101065-Trovato1], our immunofluorescence assay demonstrated a nuclear pattern that was of clinical significance. A similar nuclear localization of the receptor of HGF c-Met has been reported in breast cancer cells, where such overexpression was related to increased metastatic potential and aggressive disease [@pone.0101065-Matteucci1].

In summary, CRC cancer aggressiveness is a complex trait that cannot be predicted with suitable accuracy by the use of an individual, single dimensional factor (microRNA, gene or protein). In contrast, a multidimensional integrated approach which utilizes data from microRNA, gene and protein analysis can generate accurate predictors of biological behavior, foster better clinical management of CRC, and shine a spotlight on molecules and molecular pathways which are associated with and potentially the cause of poor outcome.
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